Key result
Hirulog as adjunctive therapy to streptokinase significantly improved early infarct-related artery patency (TIMI 2 or 3 flow at 90 minutes) compared to heparin (77% vs 47%, P<0.05).
Why the study?
Does Hirulog improve early angiographic patency compared to heparin when used as adjunctive therapy to streptokinase in patients with acute myocardial infarction?
Population
45 patients with acute myocardial infarction
Comparison
Hirulog as adjunctive therapy to streptokinase vs Heparin as adjunctive therapy to streptokinase
Design
RCT, randomized to Hirulog or heparin (2:1 ratio)
Follow-up
4.7 days
Authors
Loading...
Favors Hirulog over heparin with streptokinase for early patency in AMI; extends evidence for direct thrombin inhibitors in reperfusion.
RCT (n=45)
2:1 ratio
Does Hirulog improve early angiographic patency compared to heparin when used as adjunctive therapy to streptokinase in patients with acute myocardial infarction?
Absolute Event Rate: 77% vs 47%
p-value: p=<0.05
In a pilot study of acute myocardial infarction, adjunctive therapy with the direct thrombin inhibitor Hirulog significantly improved early infarct-related artery patency compared to heparin.
Lidón et al. (1994) conducted an RCT in acute myocardial infarction (n=45). Hirulog vs. Heparin was evaluated on TIMI 2 or 3 flow after 90 minutes (p=<0.05). Hirulog as adjunctive therapy to streptokinase significantly improved early infarct-related artery patency (TIMI 2 or 3 flow at 90 minutes) compared to heparin (77% vs 47%, P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: